Fibrinolytic activity of venous blood of patients with multiple sclerosis. 1969

I S Menon, and H A Dewar, and D J Newell

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D002087 Butyrates Derivatives of BUTYRIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxypropane structure. Butyrate,n-Butyrate,Butanoic Acids,Butyric Acids,Acids, Butanoic,Acids, Butyric,n Butyrate
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

I S Menon, and H A Dewar, and D J Newell
August 1979, Gastroenterology,
I S Menon, and H A Dewar, and D J Newell
December 1975, Polski przeglad chirurgiczny,
I S Menon, and H A Dewar, and D J Newell
January 1985, VASA. Zeitschrift fur Gefasskrankheiten,
I S Menon, and H A Dewar, and D J Newell
September 1967, The American journal of the medical sciences,
I S Menon, and H A Dewar, and D J Newell
July 1986, Klinische Wochenschrift,
I S Menon, and H A Dewar, and D J Newell
July 1986, Journal of vascular surgery,
I S Menon, and H A Dewar, and D J Newell
September 1969, Il Policlinico. Sezione pratica,
I S Menon, and H A Dewar, and D J Newell
May 1981, Journal of neuropathology and experimental neurology,
I S Menon, and H A Dewar, and D J Newell
April 1977, Polski tygodnik lekarski (Warsaw, Poland : 1960),
I S Menon, and H A Dewar, and D J Newell
July 1976, Indian journal of pathology & microbiology,
Copied contents to your clipboard!